Global Search

Hide Filters

Showing 1489 results

Press release / Nov 16, 2016

Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer

First results from global registrational trial of CAR T therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia Sub-group analyses from pivotal MONALEESA-2 trial of…
Pulse Update / Apr 04, 2024

Novartis confirms plans to file for Pluvicto® pre-taxane label expansion in H2 2024 based on latest data from Phase III PSMAfore study
Pulse Update / Apr 09, 2024

Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2
Press release / Oct 29, 2020

Novartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasis

Latest data show Cosentyx® provides fast and strong skin clearance, significant improvement in quality of life and a favorable safety profile1,2 Moderate-to-severe psoriasis affects more than…
Press release / Dec 08, 2023

Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions

With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in…
Press release / May 31, 2024

Latest analysis of Novartis NATALEE study shows Kisqali® reduces risk of cancer recurrence for early breast cancer patients with high-risk node-negative disease

Addition of Kisqali® (ribociclib) to endocrine therapy (ET) demonstrated a 28% risk reduction in invasive disease-free survival (iDFS) in subgroup of patients with node-negative (N0) disease at…
Press release / Aug 27, 2015

Le Novartis International BioCamp souligne le rôle de la collaboration et de la diversité pour stimuler l'innovation et inspirer les futurs leaders scientifiques.

L'International Biotechnology Leadership Camp (BioCamp) mobilise des étudiants autour d'avancées scientifiques et d'opportunités entrepreneuriales. Ce programme interactif a réuni au siège de…
Press release / May 12, 2022

Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer

Latest in HR+/HER2- metastatic breast cancer, including data on CDK recycling with Kisqali® plus endocrine therapy, further MONALEESA-2 quality of life and overall survival analyses, and a new…
Press release / May 25, 2024

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical…
Press release / Aug 02, 2016

Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma

US Food and Drug Administration (FDA) grants approval for CyPass Micro-Stent for sale in the US, expanding Alcon's surgical presence to treat glaucoma The CyPass Micro-Stent is designed to…